Novozymes

Novozymes A/S

Type	Publicly-traded Aktieselskab (OMX: NZYM B)
Industry	Biotechnology
Founded	1925
Headquarters	Bagsværd, Denmark
Key people	Henrik Gürtler (Chairman), Steen Riisgaard (President and CEO)
Products	Enzymes, microorganisms
Revenue	DKK 9.724 billion (2010)[1]
Operating income	DKK 2.117 billion (2010)[1]
Profit	DKK 1.614 billion (2010)[1]
Employees	5,432 (2010)[1]
Website	www.novozymes.com

Novozymes is a biotech-based company, headquartered in Denmark and employing approximately 5,400 people in 30 countries. Novozymes A/S’ B shares are listed on the NASDAQ OMX Nordic.

Business areas

Novozymes' business in divided into three areas: Enzymes for industrial use, Microorganisms and Biopharmaceutical ingredients accounting for respectively 94%, 4% and 2% of sale, respectively (2010) ^[2]. Novozymes markets approximately 700 different products worldwide.

Enzymes

Enzymes are divided into the following categories:

• Household care. Enzymes used in laundry detergents and automatic dish washing machines.
• Technical enzymes. The most important products in this business area are enzymes for the starch, textile and bioethanol industries, as well as enzymes for the leather and forest products industries and various other smaller industries.
• Food enzymes. Food enzymes include products for the baking, brewing, beverage alcohol, fruit juice and wine industries, and other food industries such as the dairy industry and the oils & fats industry.
• Feed enzymes. Includes enzymes for the animal feed industries.

Biopharmaceuticals

Biopharmaceutical ingredients comprise of regulatory-compliant, protein based products and technologies dedicated to the biopharmaceutical industry, adding value through efficiency - from manufacture to final drug formulation and drug delivery.

Microorganisms

The microorganisms business area includes microorganisms for:

• Institutional and household cleaning
• Wastewater treatment
• Aquaculture
• Bioagriculture

Ownership

The Novozymes A share capital is held by Novo A/S, a wholly owned subsidiary of the Novo Nordisk Foundation. In addition, Novo A/S holds 5,826,280 B shares, which overall gives Novo A/S 25.5% of the total share capital and 70.1% of the votes.

Novozymes A/S' B shares are listed on the NASDAQ OMX Nordic and are traded under the abbreviated name NZYM B and the ID code/ISIN DK0010272129. The B shares are issued in units of DKK 10.

Each A share carries the right to cast one hundred votes at the company's shareholders' meeting, each B share the right to cast ten votes.

Timeline

• 1925 Novo Terapeutisk Laboratorium (hereafter called Novo) founded with the aim to produce insulin.
• 1941 Novo launches its first enzyme, trypsin, extracted from the pancreas of animals and used to soften leather.
• 1963 Alcalase – Novo’s first detergent enzyme produced by fermentation.
• 1984 Launch of Maltogenase® for the starch industry. The world’s first enzyme for industrial use produced by genetically modified organisms.
• 1987 Launch of Lipolase®. The world's first fat-splitting enzyme for detergents manufactured with genetically engineered microorganisms.
• 2000 Novo splits into three separate companies operating under the umbrella of the Novo Group: Novo A/S, Novo Nordisk A/S, and Novozymes A/S. Initial offering of Novozymes shares: DKK 150. Revenue (turnover) in year 2000: DKK 5,033 million.
• 2001 Novozymes launches a new business strategy, expanded to include initiatives outside the core enzyme business.
• 2003 Novozymes buys five smaller companies to form microorganism business unit.
• 2007 Novozymes forms new biopharmaceutical ingredients business unit based on the acquisitions of three smaller companies.
• 2010 Novozymes acquires Turfal (Brazil) to strengthen position in bioagriculture market.
• 2010 Novozymes announces plans to acquire EMD/Merck Crop BioScience Inc. making the largest major player in sustainable solutions for the agricultural biologicals industry.

References and footnotes

1. ^ ^{a b c d} "Annual Report 2010". Novozymes. http://www.novozymes.com/en/investor/financial-reports/Documents/EN.pdf. Retrieved 21 January 2011. 
2. ^ The Novozymes Report 2010

External links

• Official website
• Fahey, Jonathan (April 22, 2010). "Are We Getting Closer to 'Clean' Ethanol?". Forbes. http://www.forbes.com/forbes/2010/0510/global-2000-10-beer-lips-ethanol-novozymes-emperor-of-enzymes.html. Retrieved May 29, 2010. 
• Forbes Magazine: "100 Corporations That Will Survive 100 Years" (January 28, 2009)